Novel CV Risk Reduction Therapies in TD2 and CVD: Consensus Decision Pathways (ACC, 2019) - Medscape

Novel CV Risk Reduction Therapies in TD2 and CVD: Consensus Decision Pathways (ACC, 2019)  Medscape

2018 expert consensus decision pathways by the American College of Cardiology for novel therapies for cardiovascular risk reduction in individuals with type 2 ...